<DOC>
	<DOCNO>NCT02390141</DOCNO>
	<brief_summary>The trial single-centre , randomize , double-blind , phase 1b trial multiple ascend dos ZP4207 administer s.c. healthy volunteer ( HV ) evaluate safety , tolerability , pharmakocinetic ( PK ) pharmacodynamic ( PD ) . Three cohort 8 subject plan . Within cohort , subject randomly assign five repeated dos ZP4207 placebo 3:1 treatment allocation trial site .</brief_summary>
	<brief_title>Multiple Ascending Doses ZP4207 Administered HV Evaluate Safety , Tolerability , PKs PDs ZP4207</brief_title>
	<detailed_description />
	<mesh_term>Hypoglycemia</mesh_term>
	<criteria>1 . Signed date informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) . 2 . Caucasian 3 . Healthy male subject . 4 . Age 18 50 year , inclusive . 5 . Body weight 70 90 kg ( inclusive ) 6 . Fasting plasma glucose concentration &lt; = 100 mg/dL . 7 . Considered generally healthy upon completion medical history , physical examination , vital sign , ECG analysis laboratory safety variable , judge Investigator . 1 . Known suspected hypersensitivity IMP related product . 2 . Previous participation trial . Participation define randomize . 3 . Previous treatment ZP4207 . 4 . Receipt medicinal product clinical development within 3 month randomization trial . 5 . History multiple and/or severe allergy drug food history severe anaphylactic reaction . 6 . Any history presence cancer except basal cell skin cancer squamous cell skin cancer judge Investigator . 7 . Any history presence clinically relevant cardiovascular , pulmonary , respiratory , gastrointestinal , hepatic , renal , metabolic , endocrinological , haematological , dermatological , neurological , osteomuscular , articular , psychiatric , systemic , ocular , infectious disease , sign acute illness judge Investigator . 8 . Any serious systemic infectious disease four week prior first dose study drug , judge Investigator . 9 . Clinically significant abnormal value haematology , biochemistry , coagulation , urinalysis judge Investigator . 10 . Supine blood pressure screening ( rest least 5 min supine position ) outside range systolic 95140 mmHg blood pressure diastolic great 90 mmHg symptom heart rate rest outside range 5090 beat per minute ( exclude whitecoat hypertension ; therefore , repeat measurement show value within range , subject include trial ) . 11 . Clinically significant abnormal standard 12lead electrocardiogram ( ECG ) 5 minute rest supine position screening , judge Investigator . 12 . Significant history alcoholism drug abuse judge Investigator consume 21 unit alcohol per week ( one unit alcohol equal 250 mL beer , one glass wine 120 mL , 20 mL spirit ) . 13 . A positive result alcohol and/or urine drug screen screen visit . 14 . Smoker ( define subject smoke 7 cigarette equivalent per week ) within last month prior screen able willing refrain smoking use nicotine substitute product one day first dose treatment period . 15 . Positive screen test Hepatitis Bs antigen Hepatitis C antibodies and/or positive result test HIV1/2 antibodies HIV1 antigen . 16 . Any medication ( prescription nonprescription drug ) within 14 day IMP administration , exception paracetamol acetylsalicylic acid occasional use treat acute pain . 17 . Blood donation blood loss 500 mL within last 3 month . 18 . Mental incapacity , unwillingness , language barrier preclude adequate understanding cooperation . 19 . Male sexually active surgically sterilize whose partner ( ) use adequate contraceptive method ( adequate contraceptive measure include surgical sterilisation , hormonal intrauterine device [ coil ] , oral hormonal contraceptive , combination spermicidecoated condom ) , willing refrain sexual intercourse first dose 1 month last dosing trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>